Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Modeling the risks and benefits of depression treatment for children and young adults.

Soeteman DI, Miller M, Kim JJ.

Value Health. 2012 Jul-Aug;15(5):724-9. doi: 10.1016/j.jval.2012.03.1390. Epub 2012 Jun 8.

2.

Use of selective serotonin reuptake inhibitors and youth suicide: making sense from a confusing story.

Kutcher S, Gardner DM.

Curr Opin Psychiatry. 2008 Jan;21(1):65-9. doi: 10.1097/YCO.0b013e3282f29853. Review.

PMID:
18281842
3.
4.

Child and adolescent depression intervention overview: what works, for whom and how well?

Maalouf FT, Brent DA.

Child Adolesc Psychiatr Clin N Am. 2012 Apr;21(2):299-312, viii. doi: 10.1016/j.chc.2012.01.001. Epub 2012 Mar 3. Review.

PMID:
22537728
5.

[SSRIs (selective serotonin reuptake inhibitors) and suicidality in adults, adolescents and children].

Tandt H, Audenaert K, van Heeringen C.

Tijdschr Psychiatr. 2009;51(6):387-93. Review. Dutch.

6.

Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study.

Pathak S, Kratochvil CJ, Rogers GM, Silva S, Vitiello B, Weller EB, March JS.

Curr Psychiatry Rep. 2005 Dec;7(6):429-34. Review.

PMID:
16318820
7.

Pharmacotherapy of major depressive disorder in adolescents.

Masi G, Liboni F, Brovedani P.

Expert Opin Pharmacother. 2010 Feb;11(3):375-86. doi: 10.1517/14656560903527226. Review.

PMID:
20102303
8.

Child and adolescent suicide: epidemiology, risk factors, and approaches to prevention.

Pelkonen M, Marttunen M.

Paediatr Drugs. 2003;5(4):243-65. Review.

PMID:
12662120
9.

Fluoxetine--do the benefits outweigh the risks in adolescent major depression?

Doggrell SA.

Expert Opin Pharmacother. 2005 Jan;6(1):147-50. Review.

PMID:
15709892
10.

[Fluoxetine: an update of its use in major depressive disorder in adults].

Gourion D, Perrin E, Quintin P.

Encephale. 2004 Jul-Aug;30(4):392-9. Review. French.

PMID:
15597466
11.

ACNP Task Force report on SSRIs and suicidal behavior in youth.

Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, Leon AC, Meltzer HY, Ryan ND, Shaffer D, Wagner KD.

Neuropsychopharmacology. 2006 Mar;31(3):473-92. Review.

12.

Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force.

Williams SB, O'Connor EA, Eder M, Whitlock EP.

Pediatrics. 2009 Apr;123(4):e716-35. doi: 10.1542/peds.2008-2415. Review.

PMID:
19336361
13.

Continuation and maintenance therapy of early-onset major depressive disorder.

Emslie GJ, Mayes TL, Ruberu M.

Paediatr Drugs. 2005;7(4):203-17. Review.

PMID:
16117558
14.

Treatment of major depression in adolescents: weighing the evidence of risk and benefit in light of black box warnings.

Lovrin M.

J Child Adolesc Psychiatr Nurs. 2009 May;22(2):63-8. doi: 10.1111/j.1744-6171.2009.00174.x. Review.

PMID:
19490276
15.

Treatment of adolescent depression: what we have come to know.

Vitiello B.

Depress Anxiety. 2009;26(5):393-5. doi: 10.1002/da.20572. Review. No abstract available.

PMID:
19404989
16.

Psychosocial treatment of depression and suicidality in adolescents.

Brunstein Klomek A, Stanley B.

CNS Spectr. 2007 Feb;12(2):135-44. Review.

PMID:
17277714
17.

Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis.

Dubicka B, Elvins R, Roberts C, Chick G, Wilkinson P, Goodyer IM.

Br J Psychiatry. 2010 Dec;197(6):433-40. doi: 10.1192/bjp.bp.109.075853. Review.

20.

WCA recommendations for the long-term treatment of generalized anxiety disorder.

Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP; World Council of Anxiety.

CNS Spectr. 2003 Aug;8(8 Suppl 1):53-61. Review.

PMID:
14767398

Supplemental Content

Support Center